Artrya Limited ( (AU:AYA) ) just unveiled an update.
Artrya Limited has successfully completed Tranche 2 of its share placement, issuing over 13.7 million ordinary shares and more than 2 million unlisted options. This move, managed by Petra Capital, aims to bolster the company’s financial position as it continues to commercialize its AI platform for coronary artery disease detection. The completion of this placement is expected to enhance Artrya’s operational capabilities and strengthen its market position in the medical technology sector.
More about Artrya Limited
Artrya Limited, based in Perth, Australia, is a medical technology company founded in 2018 and listed on the Australian Securities Exchange in 2021. The company specializes in applied artificial intelligence for healthcare, focusing on improving the diagnosis of coronary heart disease through its patented AI platform. Artrya collaborates with clinicians to provide a comprehensive overview of at-risk patients and has developed deep-learning algorithms aimed at predicting and preventing acute coronary events.
YTD Price Performance: 28.30%
Average Trading Volume: 269,935
Technical Sentiment Signal: Sell
See more insights into AYA stock on TipRanks’ Stock Analysis page.